Drug shortage
Oxaliplatin Injection · Teva Pharmaceuticals USA, Inc.
FDA drug shortage · To Be Discontinued · updated Oct 11, 2024
Key facts
| Generic name | Oxaliplatin Injection |
|---|---|
| Company | Teva Pharmaceuticals USA, Inc. |
| Presentation | Injection, 100 mg/20 mL (NDC 0703-3986-01) |
| Dosage form | Injection |
| Strength | 100 mg/20 mL |
| Status | To Be Discontinued |
| Therapeutic category | Oncology |
| Package NDCs | 0703-3986-01 |
| First posted | Oct 11, 2024 |
| Last updated | Oct 11, 2024 |
| Discontinued | Oct 11, 2024 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: